Evidence map›Paper›PMID 31970291›Full record

ArticleNPJ digital medicine2020

mHealth and wearable technology should replace motor diaries to track motor fluctuations in Parkinson's disease.

M Kelley Erb, Daniel R Karlin, Bryan K Ho, Kevin C Thomas, Federico Parisi, Gloria P Vergara-Diaz, Jean-Francois Daneault, Paul W Wacnik, Hao Zhang, Tairmae Kangarloo and 6 more

Open access · goldAbstract read
In one paragraph

Article in NPJ digital medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Role of zonisamide in advanced Parkinson's disease: a randomized placebo-controlled study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Trial
  5. Trial
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

M Kelley Erb1Early Clinical Development, Pfizer, Inc, Cambridge, MA USA.ORCID 0000-0002-6011-5702
Daniel R Karlin1Early Clinical Development, Pfizer, Inc, Cambridge, MA USA.
Bryan K Ho3Department of Neurology, Tufts University School of Medicine, Boston, MA USA.
Kevin C Thomas4Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA USA.
Federico Parisi5Department of Physical Medicine and Rehabilitation, Harvard Medical School, Spaulding Rehabilitation Hospital, Charlestown, MA USA.
Gloria P Vergara-Diaz5Department of Physical Medicine and Rehabilitation, Harvard Medical School, Spaulding Rehabilitation Hospital, Charlestown, MA USA.
Jean-Francois Daneault5Department of Physical Medicine and Rehabilitation, Harvard Medical School, Spaulding Rehabilitation Hospital, Charlestown, MA USA.
Paul W Wacnik1Early Clinical Development, Pfizer, Inc, Cambridge, MA USA.
Hao Zhang1Early Clinical Development, Pfizer, Inc, Cambridge, MA USA.
Tairmae Kangarloo1Early Clinical Development, Pfizer, Inc, Cambridge, MA USA.
Charmaine Demanuele1Early Clinical Development, Pfizer, Inc, Cambridge, MA USA.
Chris R Brooks4Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA USA.
Craig N Detheridge4Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA USA.
Nina Shaafi Kabiri4Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA USA.ORCID 0000-0001-8951-2237
Jaspreet S Bhangu4Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA USA.
Paolo Bonato5Department of Physical Medicine and Rehabilitation, Harvard Medical School, Spaulding Rehabilitation Hospital, Charlestown, MA USA.
Boston University · USPfizer (United States) · USHarvard University · USTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurately monitoring motor and non-motor symptoms as well as complications in people with Parkinson's disease (PD) is a major challenge, both during clinical management and when conducting clinical trials investigating new treatments. A variety of strategies have been relied upon including questionnaires, motor diaries, and the serial administration of structured clinical exams like part III of the MDS-UPDRS. To evaluate the potential use of mobile and wearable technologies in clinical trials of new pharmacotherapies targeting PD symptoms, we carried out a project (project BlueSky) encompassing four clinical studies, in which 60 healthy volunteers (aged 23-69; 33 females) and 95 people with PD (aged 42-80; 37 females; years since diagnosis 1-24 years; Hoehn and Yahr 1-3) participated and were monitored in either a laboratory environment, a simulated apartment, or at home and in the community. In this paper, we investigated (i) the utility and reliability of self-reports for describing motor fluctuations; (ii) the agreement between participants and clinical raters on the presence of motor complications; (iii) the ability of video raters to accurately assess motor symptoms, and (iv) the dynamics of tremor, dyskinesia, and bradykinesia as they evolve over the medication cycle. Future papers will explore methods for estimating symptom severity based on sensor data. We found that 38% of participants who were asked to complete an electronic motor diary at home missed ~25% of total possible entries and otherwise made entries with an average delay of >4 h. During clinical evaluations by PD specialists, self-reports of dyskinesia were marked by ~35% false negatives and 15% false positives. Compared with live evaluation, the video evaluation of part III of the MDS-UPDRS significantly underestimated the subtle features of tremor and extremity bradykinesia, suggesting that these aspects of the disease may be underappreciated during remote assessments. On the other hand, live and video raters agreed on aspects of postural instability and gait. Our results highlight the significant opportunity for objective, high-resolution, continuous monitoring afforded by wearable technology to improve upon the monitoring of PD symptoms.

Indexed as

BiomarkersDrug developmentOutcomes researchParkinson's disease

Identifiers

PMID31970291
PMCPMC6969057
OpenAlexW2999310244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.